Clinical Trials Directory

Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.

Preterm birth is the leading cause of neonatal death and a significant cause of life long disability and health problems. It has been shown that the drug 17-hydroxyprogesterone caproate can help reduce the risk of preterm delivery in women with certain risk factors for preterm birth. We hope to learn whether this same medication can be used to prolong pregnancy in a group of patients in whom this medication has not been previously studied. Specifically, we hope to learn whether progesterone supplementation will delay delivery in women with pre-term, premature rupture of membranes (PPROM).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : 17-Hydroxyprogesterone Caproate
  • other : Caster Oil injections

Phase: Phase 1/Phase 2


Ages Eligible For Study:

N/A - N/A

Inclusion Criteria

1. 18yr of age 2. Singleton pregnancy 3. PPROM confirmed on clinical exam 4. GA between 24+0 and 33+5 wk 5. Ability to understand consent in either English or Spanish

External Links

Explore related trials

Contact information

Primary Contact:

Cynthia Willson, RN 650-724-6372

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: